Home
CONCORDBIO.NS

Concord Biotech Limited

NSEHealthcare
₹1,282.50
-0.28%-₹3.60 today
₹0.00₹0.00
Ask Warren
Open
₹0.00
Prev close
₹1,286.10
Day range
₹0 – ₹0
52W range
₹987 – ₹1,980
Volume
1.2L
Avg vol (20D)
2.8L
Mkt cap
₹13,337.52Cr
P/E TTM
51.4×

Trade Concord Biotech Limited with Artha

Sign in to place orders, set alerts, and sync your watchlist.

Sign in to trade

Company Metrics

Revenue (ttm)₹1054.89 Cr
Net Income (ttm)₹0.00
Shares Out10.46 Cr
EPS (ttm)
Forward PE
Dividend
Ex-Dividend DateInvalid Date

Trading Metrics

Beta0.42

About CONCORDBIO.NS

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

IndustryBiotechnology
SectorHealthcare
Employees0
Stock ExchangeNSE
Ticker SymbolCONCORDBIO.NS
CONCORDBIO.NS · NSE
Financial Performance

In 2026, Concord Biotech Limited's revenue was ₹1054.89 Cr, an decrease of +24.10% compared to the previous year. Earnings were ₹0.00, an decrease of +37.00%.

Revenue (2026)
₹1054.89 Cr
-24.10% YoY
Earnings (2026)
₹0.00
-37.00% YoY
Year-over-Year Growth
Revenue
-24.10%
Earnings
-37.00%

News

Save watchlists across devicesSet price alerts that buzz your phoneConnect Zerodha for one-tap trades
Create free account

We use analytics cookies to understand how you use Artha and improve your experience. No data is sold to third parties.